Literature DB >> 34460048

Comprehensive approach to cardiac amyloidosis care: considerations in starting an amyloidosis program.

Brett W Sperry1, Julie A Khoury2, Shahzad Raza3, Julie L Rosenthal4.   

Abstract

Amyloidosis is a multisystem disease which continues to present in later stages due to delayed diagnosis. Once the disease is identified, the coordination of ongoing care and treatment becomes complex and often involves multiple specialists. As knowledge of the disease grows, healthcare providers within institutions have organized to create comprehensive amyloidosis programs to better serve patients in the region. In this review, we present considerations in starting a cardiac amyloidosis program from two institutions that have recently started such programs. Identification of multidisciplinary stakeholders, development of overarching program goals, creation of institutional buy-in, and emphasis on program growth and development are tenets of a successful program. The creation and growth of an amyloidosis program has the potential to raise awareness for the disease and benefit patients and institutions alike.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiomyopathy; Heart failure; Immunoglobulin; Light chain; Multiple myeloma; Transthyretin

Mesh:

Year:  2021        PMID: 34460048     DOI: 10.1007/s10741-021-10163-0

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  18 in total

1.  Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

Authors:  Shaji K Kumar; Morie A Gertz; Angela Dispenzieri
Journal:  J Clin Oncol       Date:  2018-11-15       Impact factor: 44.544

2.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.

Authors:  Martha Grogan; Christopher G Scott; Robert A Kyle; Steven R Zeldenrust; Morie A Gertz; Grace Lin; Kyle W Klarich; Wayne L Miller; Joseph J Maleszewski; Angela Dispenzieri
Journal:  J Am Coll Cardiol       Date:  2016-09-06       Impact factor: 24.094

3.  Increasing Rate of Hospital Admissions in Patients With Amyloidosis (from the National Inpatient Sample).

Authors:  Brett W Sperry; Ibrahim M Saeed; Shahzad Raza; Kevin F Kennedy; Mazen Hanna; John A Spertus
Journal:  Am J Cardiol       Date:  2019-09-10       Impact factor: 2.778

Review 4.  Emerging Advances in the Management of Cardiac Amyloidosis.

Authors:  Michael N Vranian; Brett W Sperry; Jason Valent; Mazen Hanna
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

5.  Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies.

Authors:  Eoin Donnellan; Oussama M Wazni; Mazen Hanna; Mohamed B Elshazly; Rishi Puri; Walid Saliba; Mohamed Kanj; Sneha Vakamudi; Divyang R Patel; Bryan Baranowski; Daniel Cantillon; Thomas Dresing; Wael A Jaber
Journal:  JACC Clin Electrophysiol       Date:  2020-07-29

6.  Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.

Authors:  Brett W Sperry; Michael N Vranian; Rory Hachamovitch; Hariom Joshi; Asad Ikram; Dermot Phelan; Mazen Hanna
Journal:  J Am Heart Assoc       Date:  2016-03-24       Impact factor: 5.501

7.  Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis.

Authors:  Christian Nitsche; Paul R Scully; Kush P Patel; Andreas A Kammerlander; Matthias Koschutnik; Carolina Dona; Tim Wollenweber; Nida Ahmed; George D Thornton; Andrew D Kelion; Nikant Sabharwal; James D Newton; Muhiddin Ozkor; Simon Kennon; Michael Mullen; Guy Lloyd; Marianna Fontana; Philip N Hawkins; Francesca Pugliese; Leon J Menezes; James C Moon; Julia Mascherbauer; Thomas A Treibel
Journal:  J Am Coll Cardiol       Date:  2020-11-09       Impact factor: 24.094

8.  Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates.

Authors:  Jose Nativi-Nicolau; Nitasha Sarswat; Johana Fajardo; Muriel Finkel; Younos Abdulsattar; Adam Castaño; Lori Klein; Alexandra Haddad-Angulo
Journal:  Clin Med Insights Cardiol       Date:  2021-05-29

9.  Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.

Authors:  Isabelle Lousada; Raymond L Comenzo; Heather Landau; Spencer Guthrie; Giampaolo Merlini
Journal:  Adv Ther       Date:  2015-10-23       Impact factor: 3.845

10.  Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT.

Authors:  Ariana Nodoushani; Mohammed Samir El-Sady; Mi-Ae Park; Gloria L Castilloveitia; Rodney H Falk; Marcelo F Di Carli; Marie Foley Kijewski; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2019-11-22       Impact factor: 3.872

View more
  1 in total

1.  Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.

Authors:  Maaike Brons; Steven A Muller; Frans H Rutten; Manon G van der Meer; Alexander F J E Vrancken; Monique C Minnema; Annette F Baas; Folkert W Asselbergs; Marish I F J Oerlemans
Journal:  Eur Heart J Open       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.